loading
前日終値:
$1.94
開ける:
$1.94
24時間の取引高:
277.47K
Relative Volume:
0.18
時価総額:
$246.14M
収益:
-
当期純損益:
$-45.44M
株価収益率:
-5.5571
EPS:
-0.35
ネットキャッシュフロー:
$-42.28M
1週間 パフォーマンス:
+8.43%
1か月 パフォーマンス:
-3.02%
6か月 パフォーマンス:
+14.88%
1年 パフォーマンス:
+33.10%
1日の値動き範囲:
Value
$1.86
$1.97
1週間の範囲:
Value
$1.80
$2.19
52週間の値動き範囲:
Value
$0.765
$4.08

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name
名前
Compass Therapeutics Inc
Name
セクター
Healthcare (1155)
Name
電話
617-500-8099
Name
住所
80 GUEST STREET, BOSTON
Name
職員
35
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
CMPX's Discussions on Twitter

CMPX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CMPX
Compass Therapeutics Inc
1.945 246.14M 0 -45.44M -42.28M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.52 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
606.66 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.26 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.11 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.00 24.70B 3.81B -644.79M -669.77M -6.24

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-02 アップグレード Leerink Partners Market Perform → Outperform
2025-02-24 開始されました Guggenheim Buy
2025-02-19 開始されました Piper Sandler Overweight
2024-12-23 開始されました D. Boral Capital Buy
2024-11-15 ダウングレード Leerink Partners Outperform → Market Perform
2024-09-16 アップグレード Ladenburg Thalmann Neutral → Buy
2023-01-31 開始されました Jefferies Buy
2023-01-27 開始されました Stifel Buy
2022-05-23 再開されました H.C. Wainwright Buy
2022-03-15 開始されました Ladenburg Thalmann Buy
2022-01-19 開始されました B. Riley Securities Buy
2021-12-22 開始されました Raymond James Outperform
2021-12-20 開始されました SVB Leerink Outperform
2021-12-15 開始されました Wedbush Outperform
すべてを表示

Compass Therapeutics Inc (CMPX) 最新ニュース

pulisher
08:36 AM

Compass Therapeutics Presents Data on Enhanced Efficacy of - GlobeNewswire

08:36 AM
pulisher
04:45 AM

Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World

04:45 AM
pulisher
Apr 27, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Apr 27, 2025
pulisher
Apr 24, 2025

It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com

Apr 23, 2025
pulisher
Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World

Apr 22, 2025
pulisher
Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Inc [CMPX] Insider GORDON CARL L sells 3,571,428 Shares – Latest News - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics begins biliary cancer trial with new drug By Investing.com - Investing.com Canada

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics begins biliary cancer trial with new drug - Investing.com

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Announces First Patient Dosed in an - GlobeNewswire

Apr 21, 2025
pulisher
Apr 14, 2025

Compass Therapeutics Insider Sold Shares Worth $5,678,571, According to a Recent SEC Filing - marketscreener.com

Apr 14, 2025
pulisher
Apr 12, 2025

Compass Therapeutics director Carl Gordon sells $5.68 million in shares By Investing.com - Investing.com UK

Apr 12, 2025
pulisher
Apr 11, 2025

Orbimed advisors sells $5.68 million in Compass Therapeutics shares By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Compass Therapeutics director Carl Gordon sells $5.68 million in shares - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Orbimed advisors sells $5.68 million in Compass Therapeutics shares - Investing.com

Apr 11, 2025
pulisher
Apr 08, 2025

Compass Therapeutics chief accounting officer acquires $28,400 in stock - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics chief accounting officer acquires $28,400 in stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics general counsel buys $30,800 in common stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics general counsel buys $30,800 in common stock - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics Executives Increase Holdings - TradingView

Apr 08, 2025
pulisher
Apr 06, 2025

Wedbush Research Analysts Lower Earnings Estimates for CMPX - The AM Reporter

Apr 06, 2025
pulisher
Apr 05, 2025

HC Wainwright Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

Leerink Partnrs Has Pessimistic Outlook of CMPX Q2 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

FY2028 EPS Estimates for Compass Therapeutics Cut by Wedbush - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint - insights.citeline.com

Apr 04, 2025
pulisher
Apr 03, 2025

Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital - The AM Reporter

Apr 03, 2025
pulisher
Apr 02, 2025

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics: Exploring Surging Potential? - timothysykes.com

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView

Apr 01, 2025

Compass Therapeutics Inc (CMPX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.65
price up icon 0.63%
$70.47
price up icon 1.28%
$32.49
price up icon 0.64%
$23.90
price up icon 1.85%
$108.35
price up icon 3.89%
biotechnology ONC
$247.87
price up icon 1.21%
大文字化:     |  ボリューム (24 時間):